Marie Bosslett, Assistant Editor

Winter Clinical Miami 2026 kicks off today with the latest dermatology updates—let us know if you're attending and stay tuned for live coverage, pearls, and interviews.

Review our content from the month of February that recognizes patients and clinicians with skin of color.

Dermatology Times is looking back on the top stories in dermatology from the month of February.

Learn more about the in-depth topics covered in the February 2026 print issue of Dermatology Times.

The FDA has assigned a Prescription Drug User Fee Act target action date of December 12, 2026.

Revance and Teoxane’s RHA Dynamic Volume earns FDA approval for midface lift, delivering natural movement and lasting cheek contour in supporting clinical trials.

Joni Jefferson, DO, spotlights skin of color dermatology, safer lasers, mentorship, and the future of aesthetic medicine during Black History Month.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of February.

BE HEARD long-term data show bimekizumab (Bimzelx) IL‑17A/F reduces hidradenitis suppurativa draining tunnels while boosting IHS4 and quality of life.

A JAMA Dermatology study found that US veterans with documented Agent Orange exposure had approximately 30% higher odds of developing acral melanoma compared with unexposed veterans.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on phase 3 remibrutinib data for CIndU subtypes, psoriasis “super responders” on risankizumab, the approval of difamilast ointment, and more.

Thrasyvoulos Tzellos, MD, PhD, explains HS’s progressive toll and how UCB’s BE HEARD bimekizumab data shows durable tunnel reduction and lasting disease improvement.

At IMCAS, Anne-Cécile Chevrier revealed new Galderma data on menopause and skin, urging earlier education and proactive treatment choices.

Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients.

Neal Bhatia, MD, explores denifanstat for acne—oral FASN inhibition that curbs sebum, boosts outcomes, and may be an alternative to antibiotics or retinoids.

BEACON phase 2 shows brepocitinib delivers dramatic, low-placebo CSAMI improvements with strong safety, Misha Rosenbach, MD reports, boosting hope for cutaneous sarcoidosis.

Novartis reports RemIND phase 3 success and submits a supplemental New Drug Application to the FDA for symptomatic dermographism.

This review of the latest dermatological studies includes insights on racial differences in PCOS-related teenage acne, CVD in patients with HS and lymphedema, propranolol for infantile hemangioma, and more.

A new US consensus clarifies chronic hand eczema (CHE) diagnosis and stepwise care, highlighting FDA-approved treatment and patient-reported outcomes.

Misha Rosenbach, MD, discussed the burden of cutaneous sarcoidosis (CS) and how emerging therapies like brepocitinib could fill this clinical need.

Real-world data from Saudi Arabia show vitiligo combination therapy with narrowband UVB or Janus kinase inhibitors drives steeper VASI improvement than monotherapy.

Real-world data on psoriasis super responders show that risankizumab drives complete skin clearance for up to 2.5 years.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on Biofrontera’s sNDA for Ameluz PDT in superficial BCC, 52-week data on rezpegaldesleukin for AD, the FDA's latest iPLEDGE REMS updates, and more.

PDPA’s 2025 survey, led by president Jamie Restivo, PA-C, reveals dermatology PA pay trends, productivity bonuses, benefits gaps, and satisfaction drivers shaping retention.

As we celebrate Valentine's Day, Mona Shahriari, MD, FAAD; Neal Bhatia, MD; Peter Lio, MD; Lisa Swanson, MD; Lawrence Schachner, MD; Julie Karen, MD; and Glynis Ablon, MD, FAAD, share why they love dermatology.

Des Fernandes, MBBCh, FRCS (Edin), pioneered microneedling as a safe skin regeneration therapy, demonstrating collagen gains and improved scars when paired with vitamins A and C.

LILAC data shows litifilimab rapidly improves CLE skin scores, fueling AMETHYST phase 3 and supporting FDA breakthrough for cutaneous lupus patients.